Journal article
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JC Barrientos, S O'Brien, JR Brown, NE Kay, NM Reddy, S Coutre, C Tam, S Mulligan, U Jaeger, S Devereux, C Pocock, T Robak, SJ Schuster, A Schuh, D Gill, A Bloor, C Dearden, C Moreno, G Cull, M Hamblin Show all
Clinical Lymphoma Myeloma and Leukemia | CIG MEDIA GROUP, LP | Published : 2018
Abstract
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. These results suggest that ibrutinib can improve quality of life while prolonging survival. Background: Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients and Methods: Measures of..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The authors would like to thank the patients who participated in the study and their supportive families, and the investigators and clinical research staff from the study centers. This study was sponsored by Pharmacyclics LLC, an AbbVie Company. Jacqueline Barrientos's work is supported in part by National Institutes of Health/National Center for Advancing Translational Sciences (grant #UL1TR00457) and the 2015 American Society of HematologyeHarold Amos Medical Faculty Development Program fellowship. Clara Plascencia assisted with collection of data. Editorial support was provided by Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.